Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch
Citi Downgrades BioAge Labs(BIOA.US) to Hold Rating, Cuts Target Price to $7
Morgan Stanley Downgrades BioAge Labs(BIOA.US) to Sell Rating, Cuts Target Price to $5
BioAge Labs Faces Sell Rating Amid Safety Concerns and Uncertain Prospects
BioAge Labs: Strategic Shifts and Developmental Progress Support Hold Rating Amidst Inherent Risks
BioAge Labs Terminates Azelapra Development
BioAge Discontinues Azelaprag Due To Liver Issues, Advances Next-Gen APJ Agonists; Nominates NLRP3 Inhibitor BGE-102, Phase 1 Data Expected By End 2025
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
BioAge Labs, Inc. (BIOA): A Bull Case Theory
Hunterbrook Capital Long Bioage Labs, Hunterbrook Media Reports
BioAge Stock Advances 14% On Novartis Research Collaboration
BioAge Labs Says It Is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
Express News | Bioage Labs Inc - May Receive up to $530M in Future Milestones
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
Morgan Stanley Downgrades BioAge Labs to Underweight From Overweight, Slashes Price Target to $5 From $40
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday
Express News | Bioage Labs Falls 76.9% After Jefferies Cuts PT on Co
Traders Eye Key Inflation Report as US Equity Futures Waver Pre-Bell
Unlock the Full List